Childhood convulsive status epilepticus: epidemiology, management and outcome

Area of Science:

• Pediatric Neurology
• Emergency Medicine
• Epileptology

Background:

• Childhood convulsive status epilepticus (CSE) is a critical medical emergency distinct from adult CSE.
• Incidence rates range from 17-23/100,000 in developed countries, with higher prevalence in younger children.
• Febrile CSE generally has a good prognosis, contrasting with the high mortality of CSE linked to central nervous system infections.

Purpose of the Study:

• To review the epidemiology, treatment, and outcomes of childhood CSE.
• To evaluate optimal first- and second-line pharmacological interventions.
• To assess the role of prehospital treatment and recurrence rates.

Main Methods:

• Review of epidemiological data and treatment studies for childhood CSE.
• Comparison of intravenous lorazepam and rectal diazepam for first-line treatment.
• Evaluation of intravenous phenytoin versus rectal paraldehyde for second-line treatment.
• Analysis of prehospital buccal midazolam use and recurrence data.

Main Results:

• Intravenous lorazepam may be superior to rectal diazepam as a first-line treatment.
• Intravenous phenytoin appears more effective than rectal paraldehyde as a second-line agent.
• Prehospital buccal midazolam is increasingly used, though unlicensed; exceeding two benzodiazepine doses increases respiratory depression risk.
• One-year recurrence rate is 17%, with approximately 3% hospital mortality.

Conclusions:

• Early intervention (within 5 minutes) is crucial for childhood CSE.
• Optimized pharmacological strategies, including IV lorazepam and IV phenytoin, can improve outcomes.
• Further research into prehospital treatments and management protocols is warranted to reduce recurrence and mortality.